Search Within

Kenneth K Ng

  1. "Thoracic Oncology"
Formats
  1. Journal Article (33)
  2. Meeting Abstract (22)
  3. Book Section (2)
Groups
  1. Department of Medicine (57)
  2. Solid Tumor Oncology Division (57)
  3. Thoracic Oncology (57)
  4. Radiology, Department of (18)
  5. Epidemiology and Biostatistics (17)
  6. Nursing (17)

More Groups

People
  1. Mark Kris (32)
  2. Vincent Miller (21)
  3. Juliana Eng (15)
  4. Lee Krug (15)
  5. Charles Rudin (13)
  6. Robert Heelan (13)

More People

Years
  1. 2024 (5)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (3)
  5. 2020 (4)
  6. 2018 (5)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. International Journal of Radiation Oncology, Biology, Physics (8)
  3. Clinical Cancer Research (7)
  4. Annals of Oncology (4)
  5. Lung Cancer (4)
  6. Cancer Chemotherapy and Pharmacology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Elsevier Inc. (14)
  3. American Association for Cancer Research (9)
  4. Oxford University Press (4)
  5. Elsevier Ireland Ltd. (3)
  6. Springer (3)

More Publishers

Results (57)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of docetaxel and vinorelbine in advanced non-small cell lung cancer (NSCLS) with analysis of bcl-2 and bax expression
    Meeting Abstract

    Krug, L. M.; Filippa, D. A.; Kris, M. G.; Zelenetz, A.; Heelan, R. T.; Grant, S. C.; Ng, K. K.; Pizzo, B. A.; Miller, V. A.
    Proceedings of the American Association for Cancer Research Annual Meeting (1999)

    Fulltext@MSK | Save
  • Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin (PDX), a new antifolate
    Meeting Abstract

    Krug, L. M.; Ng, K. K.; Miller, V. A.; Heelan, R. T.; Tong, W.; Kelly, J.; Sirotnak, F. M.; Kris, M. G.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination
    Journal Article

    Krug, L. M.; Grant, S. C.; Miller, V. A.; Ng, K. K.; Kris, M. G.
    Seminars in Oncology (1999)

    Fulltext@MSK | Save
  • Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with Stage III nonsmall cell lung carcinoma
    Journal Article

    Ng, K. K.; Kris, M. G.; Ginsberg, R. J.; Heelan, R. T.; Pisters, K. M. W.; Miller, V. A.; Grant, S. C.; Bains, M.; Rusch, V.; Rosenzweig, K. E.; more...
    Cancer (1999)

    Fulltext@MSK | Save
  • New chemotherapeutic agents in NSCLC
    Book Section

    Miller, V. A.; Ng, K. K.; Grant, S. C.; Early, E.; Kris, M. G.
    In Roth, J. A.; Cox, J. D.; Hong, W. K. (Eds.) Lung Cancer. 2nd ed (1998)

    Fulltext@MSK | Save
  • The development of docetaxel (Taxotere) in non-small cell lung cancer
    Journal Article

    Kris, M. G.; Miller, V. A.; Ng, K. K.; Grant, S. C.
    Seminars in Oncology (1997)

    Fulltext@MSK | Save
  • Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
    Journal Article

    Miller, V. A.; Ng, K. K.; Grant, S. C.; Kindler, H.; Pizzo, B.; Heelan, R. T.; von Roemeling, R.; Kris, M. G.
    Annals of Oncology (1997)

    Fulltext@MSK | Save